2023 World Conference on Lung Cancer (Posters)-EP07.05. The Efficacy of Neoadjuvant Chemoimmunotherapy versus Neoadjuvant Chemotherapy in Resectable NSCLC, a Comparison Research from Real World

EP07.05. The Efficacy of Neoadjuvant Chemoimmunotherapy versus Neoadjuvant Chemotherapy in Resectable NSCLC, a Comparison Research from Real World - PDF(Slides)

Back to course

Pdf Summary

This study compared the efficacy of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy in patients with resectable non-small cell lung cancer (NSCLC) and determined factors related to prognosis. The researchers conducted a retrospective study from real-world data and evaluated radiological and pathological responses to the therapies. <br /><br />A total of 57 patients received neoadjuvant chemoimmunotherapy, while 46 patients received neoadjuvant chemotherapy. The neoadjuvant chemoimmunotherapy group had higher rates of objective response (OR), major pathological response (MPR), and pathological complete response (cPR) compared to the neoadjuvant chemotherapy group. The OR rate was 75% in the chemoimmunotherapy group, compared to 52% in the chemotherapy group. The MPR rate was 63% in the chemoimmunotherapy group, compared to 22% in the chemotherapy group. The cPR rate was 37% in the chemoimmunotherapy group, compared to 9% in the chemotherapy group.<br /><br />Additionally, the neoadjuvant chemoimmunotherapy group showed more favorable recurrence-free survival (RFS) and overall survival (OS) compared to the chemotherapy group. The researchers found a strong correlation between MPR status and RFS in patients receiving neoadjuvant chemoimmunotherapy.<br /><br />Based on these findings, the researchers concluded that neoadjuvant immunotherapy combined with chemotherapy is superior in terms of producing high response rates and offering better prognosis in patients with resectable NSCLC. They recommend this combination therapy as a treatment option for these patients. The study suggests that MPR status can be a significant predictor for RFS in patients undergoing neoadjuvant chemoimmunotherapy.<br /><br />Overall, this research provides evidence regarding the efficacy difference between neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy in resectable NSCLC patients and emphasizes the importance of considering the combined therapy approach for improved outcomes.

Asset Subtitle

Xinying Xue

Meta Tag

Speaker Xinying Xue

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

neoadjuvant chemoimmunotherapy

neoadjuvant chemotherapy

non-small cell lung cancer

prognosis

retrospective study

radiological response

pathological response

objective response

major pathological response

resectable NSCLC